Role of Th17 cells and interleukin 17 in graft-versushost disease and graft-versusleukemia reactivity - Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation - page 294

[119] Bucher C, Koch L, Vogtenhuber C, Goren E, Munger M, Panoskaltsis-Mortari A, et al.
IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T
regulatory cell generation. Blood 2009;114:5375-84.
[120] Oh I, Ozaki K, Meguro A, Hatanaka K, Kadowaki M, Matsu H, et al. Altered effector CD4 +
T cell function in IL-21R −/− CD4 + T cell-mediated graft versus host disease. J Immunol
2010;185:1920-6.
[121] Hanash AM, Kappel LW, Yim NL, Nejat RA, Goldberg GL, Smith OM, et al. Abrogation
of donor T cell IL-21 signaling leads to tissue-specific modulation of immunity and
separation of GVHD from GVL. Blood 2011;118:446-55.
[122] Meguro A, Ozaki K, Oh I, Hatanaka K, Matsu H, Tatara R, et al. IL-21 is critical for GVHD
in a mouse model. Bone Marrow Transplant 2010;45:723-9.
[123] Hippen KL, Bucher C, Schirm DK, Bearl AM, Brender T, Mink KA, et al. Blocking IL-21
signaling ameliorates xenogeneic GVHD induced by human lymphocytes. Blood
2012;119:619-28.
[124] Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin 17
family members. Immunity 2011;34:149-62.
[125] Wolk K, Sabat R. Interleukin 22: a novel T and NK-cell derived cytokine that regulates
the biology of tissue cells. Cytokine Growth Factor Rev 2006;17:367-80.
[126] Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Karow M, Flavell RA. Inter-
leukin 22 but not interleukin 17 provides protection to hepatocytes during acute liver
inflammation. Immunity 2007;27:647-59.
[127] Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Stevens S, Flavell RA. Innate
and adaptive interleukin 22 protects mice from inflammatory bowel disease. Immunity
2008;29:947-57.
[128] Dudakov J, Hanash AM, Jenq RR, Young LF, Ghosh A, Singer NV, et al. Interleukin 22
drives endogenous thymic regeneration in mice. Science 2012;336:91-5.
[129] Kryczek I, Wei S, Szeliga W, Vatan L, Zou W. Endogenous IL-17 contributes to reduced
tumor growth and metastasis. Blood 2009;114:357-9.
[130] Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor
growth through an IL-6-sts3 signaling pathway. J Exp Med 2009;206:1457-64.
[131] Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, et al. A human colonic
commensal promotes colon tumorigenesis via activation of T helper type 17 T cell
responses. Nat Med 15: 1016-22.
[132] Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, et al. Tumor-specific
TH17 polarized cells eradicate large established melanoma. Blood 2008;112:362-73.
[133] Das R, Komorowski R, Hessner MJ, Subramanian H, Huettner CS, Cua D, et al.
Blockade of interleukin 23 signaling results in targeted protection of the colon and
allows for separation of graft versus host and graft versus leukemia responses. Blood
2010;115:5249-58.

297